Generally, what we understand when we first hear about Cialis is the fact that this is the first true competitor of Viagra as it fights against erectile dysfunction as well as the first mentioned. Viagra appeared in 1998 and registered a high success generally for the fact that it was the first product of this kind. Nowadays a new successful product was attributed to ICOS Corporation which is to shatter the unbelievable success of Viagra. The series isn't ending here; anyway, as another one called Levitra.

First of all, there should be mentioned that the sell market of Cialis has reached an enormous level which is bound to put aside the success registered by Viagra in the late 90's. What is important is the fact that from around thirty million people suffering from erectile dysfunction in the USA and another estimated number of one hundred and seventy five million abroad who are having this dysfunction and using these products, only a little part are using Viagra.

Like Viagra, an estimated number of eighty percent of the people who have tried Cialis have had the opportunity and chance in the mean time to have an erection as well as sexual acts but in comparison with Viagra, the effects and potential of the user lasted for more than thirty six hours after taking the pill; in this period of time the effects were almost constant. A possible explanation for this is the fact that Cialis persists longer in the body than Viagra does. The period of time for blood levels to fall fifty percent for Viagra records four hours, while Cialis makes it up to seventeen hours. This can signify that a twenty five percent of the original doze of Cialis is still in the body at that time.

To conclude, it may be said that Cialis has finally shattered the’ unbreakable’ myth of Viagra by adding more tough points to the well-known advantages of Viagra. Logically, it is of a higher quality technique than Viagra this being the reason for the extreme surpassing. Let’s hope things will not remain this way and will improve more and more up to perfection.

Food cravings and drug addiction affected the brain similarly in studies, suggesting new weight-loss medicines may help treat recovering addicts.

Brain scans of 18 cocaine addicts found that when they thought about drugs they exhibited higher levels of dopamine, a chemical tied to feelings of reward and pleasure, in a brain region that's also activated by food deprivation. Other studies showed reduced sensitivity in the reward circuits of both addicts and obese people, possibly leading them to compensate with drugs or overeating.

The data is to presented Friday at a meeting in San Francisco. Pfizer Inc., Sanofi-Aventis SA and Bristol-Myers Squibb Co. are developing new types of diet pills that work by blocking hunger signals in the brain. Some U.S. health officials hope to capitalize on the drugmakers' research by testing the compounds on smoking, alcoholism and other substance abuse.

While drugmakers are racing to gain a piece of the market for treating the two-thirds of Americans who are overweight, companies so far have been reluctant to invest in new addiction treatments. Acomplia, which was introduced in Europe in July, suffered its third delay in U.S. approval this week. Until medicines are cleared for sale by the Food and Drug Administration, scientists need the backing of companies to gain access to test their compounds.

One of Monroe County's largest employers could become the world's largest drug company if an expected deal takes place.

Sanofi-Aventis and Bristol-Myers Squibb are planning a friendly merger, according to multiple reports.

Sanofi, based in France, has more than 1,500 employees in the Poconos. If Sanofi buys U.S.-based Bristol-Myers, it would top Pfizer as the biggest pharmaceutical company in the world.

The merger would increase Sanofi's U.S. sales force in advance of its launch of a new anti-obesity drug called Acomplia, according to Business Week.

Industry experts say the biggest merger benefit for Sanofi would be tapping the Bristol-Myers pipeline of new products as both companies face a decrease in sales when many of their best sellers lose their patent protection in a few years.

Sanofi-Aventis was created in 2004 when Aventis accepted a bid for $65.4 billion from French drug-maker Sanofi-Synthelabo. The deal created the world's third-largest pharmaceutical company.

Sanofi, the largest maker of flu vaccine, is routinely praised by Monroe County leaders for providing high-paying, high-tech jobs.

Sanofi's products include allergy medicine Allegra and sleep aid Ambien. Bristol-Myers' products include the blood-thinner Plavix. Sanofi-Aventis conducts business in the U.S. through its headquarters in Bridgewater, N.J. The company has 16,000 employees in the U.S.

Source: poconorecord.com